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Endometrial cancer is the most common gynaecological malignancy and its incidence is increasing. In 1998, international
federation of gynaecologists and obstetricians (FIGO) required a change from clinical to surgical staging in endometrial cancer,
introducing pelvic and paraaortic lymphadenectomy. This staging requirement raised controversies around the importance of
determining nodal status and impact of lymphadenectomy on outcomes. There is agreement about the prognostic value of
lymphadenectomy, but its extent, therapeutic value, and beneﬁts in terms of survival are still matter of debate, especially in early
stages. Accurate preoperative risk stratiﬁcation can guide to the appropriate type of surgery by selecting patients who beneﬁt of
lymphadenectomy. However, available preoperative and intraoperative investigations are not highly accurate methods to detect
lymph nodes and a complete surgical staging remains the most precise method to evaluate extrauterine spread of the disease.
Laparotomy has always been considered the standard approach for endometrial cancer surgical staging. Traditional and robotic-
assisted laparoscopic techniques seem to provide equivalent results in terms of disease-free survival and overall survival compared
to laparotomy. These minimally invasive approaches demonstrated additional beneﬁts as shorter hospital stay, less use of pain
killers, lower rate of complications and improved quality of life.
1.Introduction
Endometrial cancer is one of the most common gynaecolog-
ical malignancies in developed countries and, unfortunately,
the incidence of endometrial cancer is rising. This may
be attributed to risk factors, like increased life expectancy,
obesity, diabetes, late menopause, and use of Tamoxifen [1–
3]. Endometrial cancer spreads towards myometrial wall,
cervix,andlymphaticstationsofpelvicandparaaorticlymph
nodes [4]. Prognosis of this malignancy depends on various
factors:histologicaltypeofthetumour,thedepthofinvasion
into the myometrium, and lymph node involvement [1–4].
Surgical management of endometrial cancer is a chal-
lenge. It is important to balance risks and beneﬁts of each
surgical option, avoiding both over- and undertreatment.
The Gynaecologic Oncology Group (GOG) trial pub-
lished in 1987, lead to a crucial change from clinical
to surgical staging. By this study, pelvic and paraaortic
lymphadenectomy have been introduced in the oncolog-
ical practice of endometrial cancer on the basis of the
international federation of gynaecologists and obstetricians
(FIGO) criteria [5]. The new FIGO classiﬁcation addressed
new information about prognostic predictors. However, the
extent of surgical staging, the deﬁnition of high-risk patients
who beneﬁt from complete staging, numbers of lymph
nodes, and anatomical limits in paraaortic area still lack
standardisation [6–10].
In the present manuscript, we sought to review the
available evidences and to discuss controversies in surgical




(2) Preoperative evaluation: Predictors of lymph node
metastasis;
(3) Intraoperative detection of lymph node metastasis;
(4) Extent of lymphadenectomy;
(5) Surgical approach for staging of endometrial cancer.2 Obstetrics and Gynecology International
2. Complete SurgicalStaging: Role of
Lymphadenectomy in Endometrial Cancer
A complete surgical staging, including lymphadenectomy is
the gold standard to evaluate lymph node involvement, the
most common site of extrauterine spread of endometrial
cancer. However, the exact role, indications, and extent of
lymphadenectomy in endometrial cancer patients remain
controversial [4, 6, 11–13]. A recent Cochrane protocol
conﬁrmed the prognostic role of lymphadenectomy, while
its therapeutic role, the advantages in terms of survival,
and extent of anatomical standardization are under debate
[4]. Lymph node metastasis has been described, as well as
one of the strongest predictors of disease recurrence and as
a guide for subsequent adjuvant therapy in patients with
positive lymph nodes. Patients with stage I disease have more
than 90% 5-year survival rate compared to those with nodal
metastasis who have survival rates ranging from 38% to 75%
[14].
In a retrospective study, Bernardini et al. veriﬁed that
a substantial number of patients with grade 1 endometrial
cancer,basedonpreoperativeandintraoperativeassessment,
had higher grade disease on ﬁnal pathology. Lymphadenec-
tomy did not aﬀect survival in these patients; however, it
could identify patients with advanced disease and assist in
tailoring adjuvant therapy for those with adverse risk factors
[15].
Nevertheless, the exact therapeutic beneﬁt in terms of
survival associated with lymphadenectomy is diﬃcult to
deﬁne, especially in early stages.
Recently, a multicentric randomized controlled trial
(ASTEC) demonstrated no evidence of beneﬁt for systematic
lymphadenectomy in terms of overall, disease-speciﬁc, and
recurrence-free survival in women with endometrial cancer.
A total of 1408 women, with a preoperative diagnosis
of endometrial cancer conﬁned to the corpus uteri were
randomized to standard surgery or standard surgery plus
pelvic lymphadenectomy. A similar proportion of women
in both groups received postoperative radiotherapy. After a
median follow up of 37 months, there was no diﬀerence
in overall survival between two groups and the analysis
of disease or treatment-related death was in favour of the
standard surgery group. Moreover, there was a signiﬁcant
beneﬁt in recurrence-free survival for the standard surgery
group, and surgical complication rates were higher in the
lymphadenectomy group [16]. The results of the ASTEC
trial, however, have been widely discussed. One important
concern to limit the generalization of these results is the
low number of lymph nodes (median of 12 lymph nodes)
removed in the lymphadenectomy group. In the literature,
excision of higher number of nodes was proved to have an
eﬀect on overall survival, especially in patients with high-
risk and intermediate-risk endometrial cancer [13, 17–19].
In addition, the ASTEC study did not assess the paraaortic
nodes, which can be involved in up to 67% of patients with
pelvic lymph node metastasis as demonstrated by Mariani
et al. [20]. Another issue to be considered is the high rate
of low-risk patients (STAGE 1A-1B grade 1-2) included
in lymphadenectomy group, and subsequently low rates of
pelvic node metastasis. Finally, the follow up duration was




compared treatment of early stage endometrial carcinoma
with and without systematic pelvic lymphadenectomy [21].
A retrospective database review considered 12,333
patients undergoing surgical staging by lymphadenectomy
and stratiﬁed them in groups: a low-risk (Stage IA, all grades
and Stage IB, grade 1 and 2) and a medium- to high-risk
group (Stage IB, grade 3 and Stage IC-IV, all grades). In
low-risk group, there was no signiﬁcant beneﬁt of nodal
resection, while a multivariate analysis demonstrated that
in the medium- to high-risk group a more extended nodal




trial cancer is based on pathological examination, but an
accurate preoperative risk stratiﬁcation guides to the appro-
priatetypeofsurgery,avoidingthemorbidityassociatedwith
unnecessary procedures [2, 6].
Both histopathological and clinical risk factors have
been identiﬁed as predictors of lymph node involvement:
histological type, grade of tumour, myometrial invasion, and
cervical inﬁltration [2–6, 14, 22, 23].
3.1. Preoperative Endometrial Biopsy. Tumour histological
grading remains the most important preoperative factor
in identifying risk status. There is only poor correlation
between histological grade of tumour based on endometrial
biopsy or D&C and ﬁnal pathology. Histological upgrading
was demonstrated in 18% of endometrial cancer patients
after deﬁnitive histological examination [2, 24, 25]. On the
other hand, the identiﬁcation of clear cell or papillary serous
carcinomawasdemonstratedtohaveincreasedriskofdistant
metastasis, even in case of endometrial conﬁned lesions [26].
3.2. Imaging Modalities and Risk Stratiﬁcation. As regards
preoperative clinical staging, several studies proposed that
identiﬁcation of patients with deep myometrial invasions
(more than 50%; FIGO stage IC) and preoperative knowl-
edge of cervical stroma inﬁltration (FIGO stage IIb) are
important determinants for surgical decision [27, 28]. Sev-
eral techniques are used to evaluate the depth of myometrial
invasion and cervical inﬁltration. In this context, Magnetic
Resonance Imaging (MRI), Computed Tomography (CT),
and Transvaginal Sonography (TVS) are the main diag-
nostic tools used. Comparing the diagnostic accuracy of
these techniques, several studies demonstrated no signiﬁcant
diﬀerences in performance for both myometrial extent and
cervical invasion [29, 30]. A recent prospective study com-
pared the high-frequency (5.0–9.0MHz) TVS and contrast-
enhancedMRIinpreoperativestagingofendometrialcancer.
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feasible and more economic imaging method with accuracy
comparable with MRI and it can be proposed as ﬁrst-line
option for evaluation of myometrial invasions and cervical
spread [31].
Someimagingmodalitiescanalsoinvestigatethestatusof
lymph nodes, but the results, to date, have been disappoint-
ing. MRI and CT/PET are statistically comparable, but have
only a limited speciﬁcity in detecting pelvic and paraaortic
node metastasis [29, 30].
4.IntraoperativeDetectionof
LymphNode Metastasis
There is currently no validated method for predicting
lymph node metastasis. Accordingly, many authors support
a comprehensive surgical staging for endometrial cancer.
Although intraoperative evaluation methods for lymph
node metastasis, as frozen section examination and node
palpations, are often used in surgical oncological practice,
there is scientiﬁc agreement that they are inaccurate.
4.1. Lymph Node Palpation. Girardi et al. found that 37% of
nodal metastases were less than 2mm and only 7% larger
than 2cm [32]. Several authors demonstrated the high false-
negative rates for intraoperative lymph node palpation (26%
by Eltabbakh and 36% by Arango et al.) [33, 34].
4.2. Frozen Section. The incidence of lymph node metastasis
is related to the depth of invasion and tumor grade.
Intraoperative frozen section might identify patients who are
atriskforextrauterinespreadandrequiredcompletesurgical
staging.
Frozen section may help to further stratify for the risk
of ﬁnal pathology but is not entirely accurate [35]. To date,
available evidence does not clearly support modulating the
extent of surgical staging according to the results of frozen
section examination.
Case et al. evaluated in a prospective-blinded study
the accuracy of frozen section in surgical management of
endometrial cancer. There was a poor correlation between
frozen and ﬁnal section: only 67% for invasion depth and
58% for tumour grade. This study demonstrated a clini-
cally relevant upstaging in 18% of patient who underwent
lymphadenectomy [36]. Another study by Frumovitz et al.
veriﬁedthatthecombinationofintraoperativefrozensection
analysis for histological grade and depth of myometrial
invasion correlates poorly with ﬁnal pathologic grade and
stage in patients with apparent grade I and II tumor [37].
The ﬁnding of negative pelvic nodes at intraoperative
frozen section has been proposed to guide further surgical
management during surgical staging of endometrial cancer.
ArecentstudybyPapadiaetal.conﬁrmedthatfrozensection
underestimated the risk of lymph node involvement in 16%
of cases when compared with ﬁnal section pathology [38].
Another trial by Pristauz et al. veriﬁed that intraoperative
frozen section of pelvic nodes is not accurate to tailor the
extent of lymphadenectomy. In this study, examination of
pelvic nodes had a sensitivity of 41% and a false negative rate
of 59% [39].
4.3. Sentinel Lymph Node Examination. In an eﬀort to
decrease the morbidity resulting from lymphadenectomy,
several authors proposed the sentinel lymph node (SN)
detection approach. Although it is still under investigation,
this technique has several potential beneﬁts in surgical
management of endometrial cancer. Data on feasibility and
utility are rapidly increasing. However, few studies have
concluded the feasibility of SN in endometrial cancer [40–
50]. It has been veriﬁed by many authors that SN detection
may help to evaluate regional lymphatic status and to
select the group of patients that must be submitted to a
complete lymphadenectomy, avoiding surgical invasiveness
in early stage cancer [49, 50]. Most investigators performed
intramyometrial or intracervical punctures [40–50]. The
identiﬁcation rates were 61.5% to 67%, when blue dye was
injected into the subserosal myometrium of the fundus, and
83% by additional injections of blue dye into the cervix [40].
The modern trend in lymphatic mapping for endometrial
cancer is through subendometrial hysteroscopic injection.
Delaloye et al. published a study evaluating hysteroscopic
injection of patent blue dye and radioactive tracer beneath
the tumour of 60 patients with endometrial carcinoma,
sentinel nodes were identiﬁed in 49 of 60 patients (82%)
[50].
5. Extentof Lymphadenectomy
Actually, the extent and anatomical limits of lymphadenec-
tomy in endometrial cancer is another topic of scientiﬁc
debate. The GOG (Gynaecologic Oncology Group) has
standardized the surgical limits of pelvic and paraaortic
lymphadenectomy including the genitofemoral nerve later-
ally, the hypogastric artery medially, the obturator nerve
posteriorly, the circumﬂex iliac vein caudally, and inferior
mesenteric artery (IMA) as cranial limit when performing
paraaortic lymphadenectomy [51].
5.1. Paraaortic Lymphadenectomy: To Do or Not To Do?
Retroperitoneal lymph node metastasis is a signiﬁcant prog-
nostic factor for patients with endometrial cancer. The risk
of paraaortic nodal metastasis can be related to the presence
of adnexal metastasis and/or pelvic lymph nodes metastasis:
paraaortic lymph nodes are positive in 38%–52% of cases
with positive pelvic lymph nodes, in 20%–57% with adnexal
metastasis, and in only 2% with negative pelvic nodes [52].
In other trials, a range from 28.6% to 66.7% of patients with
pelvic metastasis had concomitant positive paraaortic nodes
[5, 52–54].
Mariani et al. demonstrated that 47% of patients with
pelvic lymph nodes metastasis also have positive paraaortic
lymph nodes or will submit a relapse in paraaortic region
[20]. Furthermore there are reports in literature showing
that increasing number of positive pelvic nodes is associ-
ated with paraaortic metastasis [55, 56]. Fujimoto et al.
reported the therapeutic signiﬁcance of complete paraaortic4 Obstetrics and Gynecology International
lymphadenectomy in 63 patients with stage IIIC endometrial
carcinoma. Despite there was no signiﬁcant diﬀerence in
disease-related survival, the authors found an improvement
in disease-related survival in patients with two or more
positive lymph nodes [57]. Mariani et al. reported the
potential therapeutic role of paraaortic lymphadenectomy
in node positive patient with endometrial cancer [58, 59].
The 5-year progression free and overall survival rates were
signiﬁcantly better in paraaortic lymphadenectomy group.
From the available studies we could conclude that paraaortic
lymphadenectomy might have a therapeutic role at least
for high-risk patients. However, further RCT are needed to
conﬁrm this conclusion.
5.2. Cranial Limit of Paraaortic Lymphadenectomy: Where
to Arrive? Moreover, the cranial extent of paraaortic lym-
phadenectomy has recently been a matter of debate. A
prospective study by Mariani et al. evaluated patients
with high-risk endometrial cancer requiring a complete
lymphadenectomy.Consideringpatientswithpositivelymph
nodes, 77% of them had paraaortic metastasis above the
IMA. The authors emphasized the importance of systematic
pelvic and paraaortic lymphadenectomy up to the renal
vessels with excision of the gonadal veins [20].
5.3. Number of Removed Lymph Nodes. Another controver-
sialissueisthenumberoflymphnodesthatmustberemoved
for proper surgical staging. Lutman et al. found that pelvic
lymph node count ≥12 is an independent prognostic factor
for both overall and progression-free survival in patients
with FIGO stage I and II with high-risk histology [18].
Another study by Cragun et al. conﬁrmed that patients
with grade 3 endometrial cancers having more than 11
pelvic nodes removed had improved overall survival and
progression-free survival compared with patients with 11
or fewer nodes removed [19]. Chan et al. have shown a
correlation between the increasing number of lymph nodes
removed and number of nodal metastasis. They concluded
that the removal of 21 to 25 nodes was considered to
signiﬁcantly increase the probability of detecting at least one
lymph node metastasis [60].
6.SurgicalApproachfor Stagingof
EndometrialCancer
Surgical treatment of endometrial cancer has traditionally
been through laparotomy. Nevertheless, in the last 15
years, the use of minimally invasive techniques is getting
widely accepted by many authors [61–64]. The laparo-
scopic approach can be either laparoscopic-assisted vaginal
hysterectomy (LAVH) or total laparoscopic hysterectomy
(TLH). These procedures proved feasible and safe when
compared with laparotomy [61–69].
The primary endpoint for trials comparing laparoscopic
and laparotomic approach is to demonstrate the equivalence
in terms of staging completeness and survival rates. Other
endpoints are hospital stay, postoperative pain, quality of life
(QOL), and health costs of the procedures. The randomized
study of the Gynaecologic Oncology Group (GOG-LAP2)
considered the laparoscopic and laparotomic surgery for
stage I-IIa, grade 1–3 endometrial cancer. There were no sig-
niﬁcant diﬀerences in terms of staging completeness, lymph
node metastasis, rate of perioperative complications, and
mortality between the two procedures. This trial veriﬁed that
although the laparoscopic approach has a longer operative
time, it has the advantage of a shorter hospital stay [61].
The quality of life is another important index in evaluation
of the therapeutic role of laparoscopy in endometrial cancer.
The same study (GOG-LAP2), through examination of QOL
indicators and from the results of validated questionnaire
SF-36, demonstrated that laparoscopy has a signiﬁcant
advantage in terms of quality of life within the ﬁrst 6 weeks.
Data from GOG-LAP2 on rate of relapse and long-term
survival are not yet available [61].
A recent meta-analysis showed that, in early stages,
laparoscopic approach is equally eﬀective as laparotomic
one in terms of overall survival, disease-free, and cancer-
related survival. Both techniques were proven equal in terms
of intraoperative complications and number of pelvic and
paraaortic node yield. Laparoscopy had additional beneﬁts
like lower blood loss and fewer postoperative complications
rates; however, it had other disadvantages in terms of longer
operative time and learning curve [63].
6.1. Use of Laparoscopy in Obese Patients with Endometrial
Cancer. The feasibility and safety of the use of laparoscopy
in obese women with endometrial cancer are other issues
of concern. Obesity and comorbidity were considered, for
many years, contraindications for laparoscopic approach.
However, comparative studies demonstrated that patients
with increased surgical risk (obese and elderly) are the ones
who most beneﬁt from the minimally invasive approach, in
terms of reduction of operative morbidity (e.g., laparotomic
wound infections and bowel obstruction), postoperative
pain, hospital stay, and time to return tofullactivity[65–70].
A recent study compared the safety and eﬃcacy of
laparoscopyandlaparotomyinsurgicalstagingofearlystages
(FIGO I-II) in obese women. Authors found no signiﬁcant
diﬀerences among the two groups regarding mean operative
time, with a signiﬁcantly higher blood loss and hospital stay
in patients treated by laparotomy [67].
Another study comparing obese and nonobese women
with laparoscopically treated stage I endometrial cancer
found no diﬀerence in operative time, pelvic node removed,
and complications, although obese group had higher blood
loss [68].
6.2. Actual Use of Laparoscopy in Endometrial Cancer Man-
agement. Despite the controversies regarding endometrial
cancer staging by laparoscopy, the use of this procedure in
oncological practice is increasingly rising. A recent follow-
up survey among members of the Society of Gynaecolog-
ical Oncology found an overall increase in the use and
indications for minimally invasive surgery in gynaecological
oncology. 91% of responders indicated that they performObstetrics and Gynecology International 5
laparoscopy in their surgical practice. Laparoscopic hysterec-
tomy for endometrial cancer staging was the most frequent
procedure performed (43%) [71].
6.3. Robotic-Assisted Surgical Approach. Since 2005, there
has been a considerable increase in the published literature
describingtheuseofrobotic-assistedsurgeryforendometrial
cancer staging [70–84]. When compared to laparotomy,
the robotic-assisted surgery had signiﬁcantly longer mean
operative time, but lymph node yields were comparable to
the open surgery. The length of hospital stay, blood loss, and
postoperative complication rates were signiﬁcantly lower for
robotically operated patients [79, 80].
Boggess et al. compared three surgical methods for
endometrial cancer staging: laparotomy, laparoscopy, and
robotic-assisted approach. Patients operated by robotic tech-
nique had shortest hospital stay, lowest estimated blood loss,
andhighestlymphnodeyield.Operativetimewasthelongest
for laparoscopy followed by robotics, with a similar laparo-
tomic conversion rates for robotic and laparoscopic groups
[81]. Robotic-assisted approach has been also proposed as a
good and feasible option for comprehensive surgical staging
in obese women with endometrial cancer [82]. Moreover,
this technique may have particular advantages for both the
obese and morbidly obese patients aﬀected with endometrial
cancer, when compared to laparoscopic approach [83, 84].
7. Conclusions
Surgical staging for endometrial cancer represents certain
beneﬁts: ﬁrstly, it is the gold standard to assess the disease
extent. Secondly, it also has a prognostic role and guides for
further treatment. The therapeutic value of lymphadenec-
tomy has not been proven in prospective studies, especially
in low-risk cases at preoperative staging.
There are many predictors of lymph nodes involvement
useful to evaluate patient’s risk categories and to guide
surgical management. TVS and MRI may accurately detect
the depth of myometrial invasion and cervical spread of the
disease, but preoperative imaging cannot accurately assess
lymph node involvement. Intraoperative assessment of node
involvement and myometrial invasion does not have the
sensitivity and speciﬁcity to select women who can avoid
lymphadenectomy from the surgical procedure.
A great challenge in surgical management of endome-
trial cancer is standardisation of pelvic and paraaortic
lymphadenectomy strategies, in order to avoid unnecessary
procedures and to oﬀer complete staging with high survival
rates.
The morbidity of lymphadenectomy appears to be
reduced with the use of laparoscopy. Numerous trials have
demonstrated the safety and feasibility of laparoscopy in
complete surgical staging for early stages of endometrial
cancer with similar nodes yields, recurrence and survival
outcomes. As expected, signiﬁcant improvements in early
and late postoperative complications, a shorter hospital stay,
a better quality of life, and less overall treatment costs
were demonstrated in many comparative studies between
laparotomy and laparoscopy. Laparoscopic approach is safe
and feasible also in obese and elderly woman with early
stageendometrialcancer,withlowrateofconversion,shorter
hospital stay, and a faster return to full activity compared
with laparotomy.
The role of robotics in endometrial cancer staging
continues to evolve and has yet to be determined deﬁnitively.
Most studies about robotic surgery show that it is a feasible
and safe option, especially for obese patients.
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